Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2579–2581. doi: 10.1128/aac.41.11.2579

Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles.

O Hantz 1, C Borel 1, C Trabaud 1, F Zoulim 1, J Dessolin 1, M Camplo 1, P Vlieghe 1, M Bouygues 1, C Trepo 1, J L Kraus 1
PMCID: PMC164169  PMID: 9371374

Abstract

The antiviral activity of a new class of N,N,N',N",NA'''-pentakis (omega-aminoalkyl) tetraazamacrocycles was evaluated in primary duck hepatocyte cultures infected with the duck hepatitis B virus (DHBV). Three of the four tested compounds were able to selectively inhibit DHBV replication by acting at an early step of the hepadnavirus infection but were associated with significant toxicity.

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Block T. M., Lu X., Platt F. M., Foster G. R., Gerlich W. H., Blumberg B. S., Dwek R. A. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2235–2239. doi: 10.1073/pnas.91.6.2235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bridger G. J., Skerlj R. T., Thornton D., Padmanabhan S., Martellucci S. A., Henson G. W., Abrams M. J., Yamamoto N., De Vreese K., Pauwels R. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem. 1995 Jan 20;38(2):366–378. doi: 10.1021/jm00002a019. [DOI] [PubMed] [Google Scholar]
  3. Chisari F. V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29–60. doi: 10.1146/annurev.iy.13.040195.000333. [DOI] [PubMed] [Google Scholar]
  4. De Clercq E., Yamamoto N., Pauwels R., Balzarini J., Witvrouw M., De Vreese K., Debyser Z., Rosenwirth B., Peichl P., Datema R. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother. 1994 Apr;38(4):668–674. doi: 10.1128/aac.38.4.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dienstag J. L., Perrillo R. P., Schiff E. R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995 Dec 21;333(25):1657–1661. doi: 10.1056/NEJM199512213332501. [DOI] [PubMed] [Google Scholar]
  6. Doong S. L., Tsai C. H., Schinazi R. F., Liotta D. C., Cheng Y. C. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8495–8499. doi: 10.1073/pnas.88.19.8495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fautz R., Husein B., Hechenberger C. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutat Res. 1991 Oct;253(2):173–179. doi: 10.1016/0165-1161(91)90130-z. [DOI] [PubMed] [Google Scholar]
  8. Fourel I., Cullen J. M., Saputelli J., Aldrich C. E., Schaffer P., Averett D. R., Pugh J., Mason W. S. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol. 1994 Dec;68(12):8321–8330. doi: 10.1128/jvi.68.12.8321-8330.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hoofnagle J. H., di Bisceglie A. M. The treatment of chronic viral hepatitis. N Engl J Med. 1997 Jan 30;336(5):347–356. doi: 10.1056/NEJM199701303360507. [DOI] [PubMed] [Google Scholar]
  10. Jilbert A. R., Wu T. T., England J. M., Hall P. M., Carp N. Z., O'Connell A. P., Mason W. S. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J Virol. 1992 Mar;66(3):1377–1388. doi: 10.1128/jvi.66.3.1377-1388.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Krüger M., Tillmann H. L., Trautwein C., Bode U., Oldhafer K., Maschek H., Böker K. H., Broelsch C. E., Pichlmayr R., Manns M. P. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg. 1996 Jul;2(4):253–262. doi: 10.1002/lt.500020402. [DOI] [PubMed] [Google Scholar]
  12. Lai C. L., Ching C. K., Tung A. K., Li E., Young J., Hill A., Wong B. C., Dent J., Wu P. C. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997 Jan;25(1):241–244. doi: 10.1002/hep.510250144. [DOI] [PubMed] [Google Scholar]
  13. Lambert V., Chassot S., Kay A., Trepo C., Cova L. In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein. Virology. 1991 Nov;185(1):446–450. doi: 10.1016/0042-6822(91)90796-e. [DOI] [PubMed] [Google Scholar]
  14. Ling R., Mutimer D., Ahmed M., Boxall E. H., Elias E., Dusheiko G. M., Harrison T. J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 1996 Sep;24(3):711–713. doi: 10.1002/hep.510240339. [DOI] [PubMed] [Google Scholar]
  15. Moraleda G., Wu T. T., Jilbert A. R., Aldrich C. E., Condreay L. D., Larsen S. H., Tang J. C., Colacino J. M., Mason W. S. Inhibition of duck hepatitis B virus replication by hypericin. Antiviral Res. 1993 Mar;20(3):235–247. doi: 10.1016/0166-3542(93)90023-c. [DOI] [PubMed] [Google Scholar]
  16. Offensperger W. B., Offensperger S., Walter E., Blum H. E., Gerok W. Suramin prevents duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 1993 Jul;37(7):1539–1542. doi: 10.1128/aac.37.7.1539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Petcu D. J., Aldrich C. E., Coates L., Taylor J. M., Mason W. S. Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology. 1988 Dec;167(2):385–392. [PubMed] [Google Scholar]
  18. Sato H., Goto W., Yamamura J., Kurokawa M., Kageyama S., Takahara T., Watanabe A., Shiraki K. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res. 1996 May;30(2-3):171–177. doi: 10.1016/0166-3542(96)00942-4. [DOI] [PubMed] [Google Scholar]
  19. Summers J., Smith P. M., Horwich A. L. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol. 1990 Jun;64(6):2819–2824. doi: 10.1128/jvi.64.6.2819-2824.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tipples G. A., Ma M. M., Fischer K. P., Bain V. G., Kneteman N. M., Tyrrell D. L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996 Sep;24(3):714–717. doi: 10.1002/hep.510240340. [DOI] [PubMed] [Google Scholar]
  21. Turin F., Borel C., Benchaib M., Kay A., Jamard C., Guguen-Guillouzo C., Trépo C., Hantz O. n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J Virol. 1996 May;70(5):2691–2696. doi: 10.1128/jvi.70.5.2691-2696.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Zoulim F., Dannaoui E., Borel C., Hantz O., Lin T. S., Liu S. H., Trépo C., Cheng Y. C. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother. 1996 Feb;40(2):448–453. doi: 10.1128/aac.40.2.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. de Vreese K., Kofler-Mongold V., Leutgeb C., Weber V., Vermeire K., Schacht S., Anné J., de Clercq E., Datema R., Werner G. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol. 1996 Feb;70(2):689–696. doi: 10.1128/jvi.70.2.689-696.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES